New Treatments for Recurrent Uterine Cancer

Keyphrases

• Recurrent Endometrial Cancer 100%
• Recurrent Uterine Cancer 100%
• Response Rate 33%
• Targeted Therapy 33%
• Human Epidermal Growth Factor Receptor 2 (HER2) 33%
• New Therapies 33%
• Endometrial Cancer 33%
• Conventional Chemotherapy 33%
• Recurrent Disease 33%
• Improved Survival 33%
• Recurring 33%
• Trastuzumab 33%
• New Drug Targets 33%
• Cytotoxic Chemotherapy 33%
• Poor Response 33%
• Pembrolizumab 33%
• Lenvatinib 33%
• Extensive Literature Search 33%
• Advanced or Recurrent Endometrial Cancer 33%
• Advanced Endometrial Cancer 33%
• Uterine Serous Cancer 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Endometrium Cancer 100%
• Uterus Cancer 100%
• Malignant Neoplasm 40%
• Recurrent Disease 20%
• Immunotherapy 20%
• Chemotherapy Regimens 20%
• Trastuzumab 20%
• Cytotoxic Chemotherapy 20%
• Pembrolizumab 20%
• Lenvatinib 20%

Medicine and Dentistry

• Uterine Cancer 100%
• Malignant Neoplasm 33%
• Targeted Therapy 33%
• Immunotherapy 16%
• Recurrent Disease 16%
• Cytotoxic Chemotherapy 16%
• Trastuzumab 16%
• Pembrolizumab 16%
• Lenvatinib 16%
• Chemotherapy 16%